Inventors list |
Assignees list |
Classification tree browser |
Top 100 Inventors |
Top 100 Assignees |
Diaz-Mitoma
Francisco Diaz-Mitoma, Ottawa CA
| Patent application number | Description | Published |
|---|---|---|
| 20110097418 | COMPOSITIONS AND METHODS FOR TREATING INFLUENZA - The present application provides compositions and methods useful for treating influenza. As described herein, the compositions and methods are based on the development of peptides and peptide combinations which exhibit immunogenic properties against influenza. In some embodiments, the peptide combinations induce a protective response against multiple strains of influenza, e.g., seasonal strains of influenza or even the new pandemic influenza A (H1N1) virus of swine origin. | 04-28-2011 |
Francisco Diaz-Mitoma, Ontario CA
| Patent application number | Description | Published |
|---|---|---|
| 20090017447 | Human Endogenous Retrovirus with Foamy-Like Properties and Uses Thereof - The invention relates to the discovery of a human endogenous retrovirus (HERV) family, Type I HERV-K (HML-2) which appear to be active in vitro and in vivo, infectious, and which have the have the salient features and properties of foamy retroviruses. Based on its natural replication in humans, and that it protects the host from viral and tumor transformation, this non-pathogenic endogenous virus could be developed as a replication competent gene therapy vector. It also is expected to have much higher efficacy than other vectors as it crosses the bloodbrain barrier and infects almost all cell types in the host (proliferating or not). It may naturally lyse tumor cells or infected cells, and thus could even be used without genetic modification. Of course, this vector could be used in traditional ways with it ability to replicate genetically removed. In addition to its value as a vector, as it is reactivated with infection, its detection could also be used to monitor the safety of gene therapy (irrespective of vector type used), as well as other biological therapies including vaccination, blood transfusion, transplantation and xenotransplantation. Finally it may be used to screen for new therapeutic and prophylactic treatments for a wide variety of diseases. | 01-15-2009 |
Franscisco J. Diaz-Mitoma, Ottawa CA
| Patent application number | Description | Published |
|---|---|---|
| 20090117141 | HIV VACCINE COMPOSITION - An anti-HIV vaccine composition is disclosed. The vaccine comprises an combination of immunogenic peptide mixtures, which mixtures may be prepared in a single synthesis. The composition collectively represents the in vivo variability seen in immunogenic epitopes from highly variable regions of HIV. Immunization with the vaccine elicits broadly reactive immunity (CTL and T helper cell responses) against the divergent strains of HIV upon which it is based. The vaccine may be formulated to target regionally distinct variability based on an HIV clade predominant in a geographical region. | 05-07-2009 |
